Journal of Applied Physiology Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Appl Physiol 93: 1377-1383, 2002; doi:10.1152/japplphysiol.00277.2002
8750-7587/02 $5.00
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tsueshita, T.
Right arrow Articles by Rubinstein, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsueshita, T.
Right arrow Articles by Rubinstein, I.
Vol. 93, Issue 4, 1377-1383, October 2002

Phospholipids modulate the biophysical properties and vasoactivity of PACAP-(138)

Takaya Tsueshita1,3, Salil Gandhi2, Hayat Önyüksel1,2, and Israel Rubinstein1,3,4

Departments of 1 Biopharmaceutical Sciences, 2 Bioengineering, and 3 Medicine, University of Illinois at Chicago, and 4 Chicago Veterans Afffairs Health Care System, West Side Division, Chicago, Illinois 60612

The purpose of this study was to elucidate the interactions between pituitary adenylate cyclase-activating peptide (PACAP)-(138) and phospholipids in vitro and to determine whether these phenomena modulate, in part, the vasorelaxant effects of the peptide in the intact peripheral microcirculation. We found that the critical micellar concentration of PACAP-(138) was 0.4-0.9 µM. PACAP-(138) significantly increased the surface tension of a dipalmitoylphosphatidylcholine monolayer and underwent conformational transition from predominantly random coil in saline to alpha -helix in the presence of distearoyl-phosphatidylethanolamine-polyethylene glycol (molecular mass of 2,000 Da) sterically stabilized phospholipid micelles (SSM) (P < 0.05). Using intravital microscopy, we found that aqueous PACAP-(138) evoked significant concentration-dependent vasodilation in the intact hamster cheek pouch that was significantly potentiated when PACAP-(138) was associated with SSM (P < 0.05). The vasorelaxant effects of aqueous PACAP-(138) were mediated predominantly by PACAP type 1 (PAC1) receptors, whereas those of PACAP-(138) in SSM predominantly by PACAP/vasoactive intestinal peptide type 1 and 2 (VPAC1/VPAC2) receptors. Collectively, these data indicate that PACAP-(138) self-associates and interacts avidly with phospholipids in vitro and that these phenomena amplify peptide vasoactivity in the intact peripheral microcirculation.

neuropeptide; amphipathic; micelles; distearoyl-phosphatidylethanolamine-polyethylene glycol; vasodilation; receptor antagonist; hamster





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online